Skip to main content

IUCT, the knowledge division of the Inkemia IUCT Group, has gained approval from the Center for the Development of Industrial Technology (CDTI) to conduct an R&D project to develop food supplements to improve quality of life for patients with type 1 hypotonic dystrophy.

The company expects this project to net them operating revenue of €105,891 over two years, in which time the group hopes to develop two products and launch them to market. To do so, it has received a €494,158 grant from the CDTI.

The project is really a continuation of the initial research partially funded through La Fundació La Mataró de TV3, from 2011 to 2014. The consortium identified six molecules that act to combat type-1 hypotonic dystrophy and presented two international patent applications. The aim of this project now is to finish what they began and develop at least two formulations.

Type-1 hypotonic dystrophy, although a rare disease, is the most common form of muscular dystrophy in adults and is defined as a multisystem genetic neuromuscular disease. It can cause mobility, cardiovascular and digestive disorders, among others. There are currently no effective therapies for patients with this disease.

Sign up for our newsletters

Stay up-to-date on the latest news, events and trends in the BioRegion.